Breaking News

AGC Biologics to Support Teikoku Seiyaku’s KTP-001

Will provide microbial contract development and manufacturing services for the recombinant human matrix metalloproteinase-7.

Author Image

By: Charlie Sternberg

Associate Editor

GMP manufacturing at AGC’s Chiba facility.

AGC Biologics, a CDMO expert, has been selected by Teikoku Seiyaku Co., Ltd. to provide microbial contract development and manufacturing services for KTP-001, a recombinant human matrix metalloproteinase-7 (rhMMP-7), to treat lumbar disc herniation.

Under the agreement, AGC Biologics will leverage its global network, with initial cell bank creation activities taking place at its Microbial Center of Excellence in Heidelberg, Germany. The project will then transition to the AGC Biologics’ facility in Chiba, Japan, for process development and GMP manufacturing to support clinical trials.

“We are delighted to support the Teikoku Seiyaku team on such an innovative project. It’s a privilege to support their vision for a therapy that could offer a new, less invasive option for patients,” said Susumu Zen-In, General Manager of the AGC Biologics Chiba site.

More AGC Biologics News

Earlier this year, AGC Biologics joined Orphan Therapeutics Accelerator’s (OTXL’s) Clinical Development Network (Orphan ClinDevNet) as a manufacturing partner.

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters